Cargando…

Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model

BACKGROUND: Although many of the factors and molecules closely associated with non-alcoholic steatohepatitis (NASH) have been reported, the role of inducible nitric oxide synthase (iNOS)-derived nitric oxide (NO) on the progression of NASH remains unclear. We therefore investigated the role of iNOS-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nozaki, Yuichi, Fujita, Koji, Wada, Koichiro, Yoneda, Masato, Kessoku, Takaomi, Shinohara, Yoshiyasu, Imajo, Kento, Ogawa, Yuji, Nakamuta, Makoto, Saito, Satoru, Masaki, Naohiko, Nagashima, Yoji, Terauchi, Yasuo, Nakajima, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387704/ https://www.ncbi.nlm.nih.gov/pubmed/25881230 http://dx.doi.org/10.1186/s12876-015-0269-3

Ejemplares similares

Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution
por: Nozaki, Yuichi, et al.
Publicado: (2015)

Soluble CD14 Levels Reflect Liver Inflammation in Patients with Nonalcoholic Steatohepatitis
por: Ogawa, Yuji, et al.
Publicado: (2013)

Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis
por: Kessoku, Takaomi, et al.
Publicado: (2016)

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
por: Honda, Yasushi, et al.
Publicado: (2017)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
por: Honda, Yasushi, et al.
Publicado: (2016)

LDL-Migration Index (LDL-MI), an Indicator of Small Dense Low-Density Lipoprotein (sdLDL), Is Higher in Non-Alcoholic Steatohepatitis than in Non-Alcoholic Fatty Liver: A Multicenter Cross-Sectional Study
por: Imajo, Kento, et al.
Publicado: (2014)

Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver
por: Niikura, Toshihiro, et al.
Publicado: (2020)

Peroxisome Proliferator-Activated Receptor Gamma Exacerbates Concanavalin A-Induced Liver Injury via Suppressing the Translocation of NF-κB into the Nucleus
por: Ogawa, Yuji, et al.
Publicado: (2012)

Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma
por: Kurokawa, Suguru, et al.
Publicado: (2022)

Impact of glucose tolerance on the severity of non‐alcoholic steatohepatitis
por: Nakamura, Akinobu, et al.
Publicado: (2011)

Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort
por: Imajo, Kento, et al.
Publicado: (2021)

Involvement of Periodontal Disease in the Pathogenesis and Exacerbation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Review
por: Kobayashi, Takashi, et al.
Publicado: (2023)

Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin
por: Ogawa, Yuji, et al.
Publicado: (2018)

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease
por: Kessoku, Takaomi, et al.
Publicado: (2020)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

Identification of differentially methylated region (DMR) networks associated with progression of nonalcoholic fatty liver disease
por: Hotta, Kikuko, et al.
Publicado: (2018)

Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
por: Yoneda, Masato, et al.
Publicado: (2022)

Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Unfolded protein response pathways regulate Hepatitis C virus replication via modulation of autophagy
por: Shinohara, Yoshiyasu, et al.
Publicado: (2013)

Obesity-Induced Coronary Microvascular Disease Is Prevented by iNOS Deletion and Reversed by iNOS Inhibition
por: Shah, Soham A., et al.
Publicado: (2023)

The dual role of iNOS in cancer()
por: Vannini, Federica, et al.
Publicado: (2015)

Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan
por: Yoneda, Masato, et al.
Publicado: (2021)

Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD
por: Nogami, Asako, et al.
Publicado: (2022)

Brain function in iNOS knock out or iNOS inhibited (l-NIL) mice under endotoxic shock
por: Schweighöfer, Hanna, et al.
Publicado: (2014)

A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs
por: Kobayashi, Takashi, et al.
Publicado: (2022)

Gastroesophageal varices evaluation using spleen‐dedicated stiffness measurement by vibration‐controlled transient elastography
por: Nagai, Koki, et al.
Publicado: (2021)

The expressions of AMACR and iNOS in prostate adenocarcinomas
por: Ozgur, Tumay, et al.
Publicado: (2013)

Targeting iNOS to increase efficacy of immunotherapies
por: Ekmekcioglu, Suhendan, et al.
Publicado: (2017)

Are Platelets Count Useful for Detecting the Grade of Steatosis?
por: Imajo, Kento, et al.
Publicado: (2015)

The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target
por: Kessoku, Takaomi, et al.
Publicado: (2021)

Upregulation of iNOS and phosphorylated eNOS in the implantation‐induced blastocysts of mice
por: Seki, Misato, et al.
Publicado: (2023)

iNOS polymorphism modulates iNOS/NO expression via impaired antioxidant and ROS content in P. vivax and P. falciparum infection
por: Kumar, Amod, et al.
Publicado: (2017)

Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)
por: Ozaki, Anna, et al.
Publicado: (2019)

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
por: Yoneda, Masato, et al.
Publicado: (2021)

Aging and Insulin Resistance: Just Say iNOS
por: Evans, Joseph L., et al.
Publicado: (2013)

Recipient iNOS but Not eNOS Deficiency Reduces Luminal Narrowing in Tracheal Allografts
por: Minamoto, Kanji, et al.
Publicado: (2002)

Sildenafil Ameliorates Gentamicin-Induced Nephrotoxicity in Rats: Role of iNOS and eNOS
por: Morsy, Mohamed A., et al.
Publicado: (2014)

The return of the Scarlet Pimpernel: cobalamin in inflammation II — cobalamins can both selectively promote all three nitric oxide synthases (NOS), particularly iNOS and eNOS, and, as needed, selectively inhibit iNOS and nNOS
por: Wheatley, Carmen
Publicado: (2007)

Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Honda, Yasushi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_emoi102r7vm40s4aaiknm62935